<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27852" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prostate-Specific Antigen</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>David</surname>
            <given-names>Michael K.</given-names>
          </name>
          <aff>Edward Via College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael David declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27852.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The primary purpose of any screening exam is to detect the early stages of a pathological condition, enabling timely&#x000a0;intervention and preventing unnecessary morbidity or mortality before clinical signs or symptoms develop. In prostate cancer screening, an elevated serum prostate-specific antigen (PSA) level is the most common initial laboratory finding, as the vast majority of men with early prostate cancer are asymptomatic. PSA is a highly sensitive but relatively nonspecific and imprecise screening tool, as both benign and malignant conditions elevate the serum marker.<xref ref-type="bibr" rid="article-27852.r1">[1]</xref> The use of PSA screening has become controversial, with differing guidelines and recommendations regarding its application across various age groups. Despite the risks associated with serum PSA screening, including the potential for unnecessary biopsies and overdiagnosis, it remains the single most useful tool for the early detection of prostate cancer, offering patients the best chance for a cure. Although the use of PSA for prostate cancer screening is somewhat controversial, its effectiveness in determining the extent of malignancy, monitoring disease progression, identifying biochemical recurrences, and evaluating treatment response is unquestionable.</p>
      </sec>
      <sec id="article-27852.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>Prostate cancer is the second most commonly diagnosed solid cancer in adult males, following non-melanoma skin cancer, and is the second leading cause of male cancer-related deaths worldwide.<xref ref-type="bibr" rid="article-27852.r2">[2]</xref>&#x000a0;In the United States alone, approximately $10 billion is spent annually on prostate cancer treatment.<xref ref-type="bibr" rid="article-27852.r3">[3]</xref>&#x000a0;This figure&#x000a0;has been increasing over the past 20 years, proportionately to the increase in prostate cancer diagnosis, likely due to the aging population and improved detection using serum PSA.<xref ref-type="bibr" rid="article-27852.r4">[4]</xref>&#x000a0;Data from the National Institutes of Health&#x000a0;indicate a 44% reduction in prostate cancer-specific mortality as PSA testing became widely available in the early 1990s.&#x000a0;The Surveillance, Epidemiology, and End Result Program (SEER) Cancer Statistics Review 1975&#x000a0;to 2017 from the National Cancer Institute indicates that prostate cancer mortality rates in the United States decreased from 39/100,000 male individuals to 19/100,000 from 1992 to 2017, which is a 51% decrease. According to simulation models, a large portion of this decrease, 45% to 70%, is believed to be due to PSA testing, as screening significantly decreased the incidence of metastatic disease.<xref ref-type="bibr" rid="article-27852.r5">[5]</xref>&#x000a0;&#x000a0;</p>
        <p>A large 2018 Kaiser Permanente study of over 400,000 patients found that annual screening in the optimal age range of 55 to 75 years reduced prostate cancer-specific mortality by 64% (95% confidence interval 50% to 78%,&#x000a0;<italic toggle="yes">P</italic>&#x0003c;.001) and overall mortality by 24%&#x000a0;(95% confidence interval 15%&#x000a0;to 34%,&#x000a0;<italic toggle="yes">P</italic>&#x0003c;.001).<xref ref-type="bibr" rid="article-27852.r6">[6]</xref>&#x000a0;As prostate cancer is slow-growing, it typically takes at least 10 years for a typical localized cancer to cause significant symptoms. According to the Social Security Administration Actuarial Tables, the average 75-year-old male in the United States has a life expectancy of just over 11 years.&#x000a0;Therefore, after 75, the vast majority of men do not receive any benefit from identifying or treating their localized prostate cancers.</p>
        <p>
<bold>General Recommendations for Prostate-Specific Antigen Testing</bold>
</p>
        <p>Comparisons between screened and unscreened populations have repeatedly shown a 50% cancer-specific mortality decrease when PSA testing is widely used over time.&#x000a0;Despite the&#x000a0;controversies regarding overdiagnosis and overtreatment,&#x000a0;most professional healthcare organizations, associations, and societies recommend PSA screening for prostate cancer.&#x000a0;Groups such as the American Academy of Family Physicians, the American Cancer Society, the American Urological Society, the Canadian Task Force on Preventive Healthcare, the European Association of Urology, and the United States Preventive Services Task Force provide recommendations on who should be screened, at what age, and how frequently.&#x000a0;Please see StatPearls' companion references, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27834">Prostate Cancer Screening</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27833">Prostate Cancer</ext-link>," for more information.</p>
        <p>Care should be taken to consider the patient's personal preferences, overall health, family history, and comorbidities. Patients should be fully informed of the risks and benefits of prostate cancer screening. Clinicians should endeavor to avoid the overtreatment of low-grade, low-stage prostate cancers, which can be accomplished by following the American Urological Association and the National Comprehensive Cancer Network (NCCN) Guidelines on treating localized prostate cancer.&#x000a0;Please see StatPearls' companion reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27833">Prostate Cancer</ext-link>," for more information.</p>
        <list list-type="bullet">
          <list-item>
            <p>PSA testing should be performed only after a comprehensive discussion of the risks and benefits of prostate cancer screenings.</p>
          </list-item>
          <list-item>
            <p>A single baseline PSA level is suggested for all men aged 40&#x000a0;to&#x000a0;45.</p>
          </list-item>
          <list-item>
            <p>Annual testing is reasonable in higher-risk men starting at 45.</p>
          </list-item>
          <list-item>
            <p>A change of &#x0003e;0.75 ng/mL per year or &#x0003e;25% is considered suspicious.</p>
          </list-item>
          <list-item>
            <p>At least 2 separate elevated PSA tests are required to confirm the increase.</p>
          </list-item>
          <list-item>
            <p>Routine screening should be discontinued in men with a life expectancy of 10 years or less based on comorbidities or by the age of 75.</p>
          </list-item>
          <list-item>
            <p>Men who fall outside of guidelines but are fully informed and are requesting testing should have a PSA level performed.</p>
          </list-item>
          <list-item>
            <p>PSA screening is not recommended for men who do not benefit from testing or refuse treatment if cancer is detected.</p>
          </list-item>
          <list-item>
            <p>High-risk individuals include those men with the following:
<list list-type="bullet"><list-item><p>African descent</p></list-item><list-item><p>Lynch syndrome</p></list-item><list-item><p>Family history of prostate cancer, especially if a first-degree relative&#x000a0;was diagnosed before 65</p></list-item><list-item><p>Family history of multiple malignancies</p></list-item><list-item><p>PSA density of 0.15 or higher</p></list-item><list-item><p>Positive germline testing for <italic toggle="yes">BRCA1 </italic>and<italic toggle="yes">&#x000a0;BRCA2</italic></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27852.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PSA is a serine protease enzyme produced by the columnar epithelium of prostatic tissue. The proenzymatic intracellular form of PSA is pro-PSA. Following cellular production, pro-PSA passes through the basal and endothelial cell layers before entering the prostatic ducts, where it is converted to active PSA, finally penetrating the capillary membranes to enter the systemic circulation.<xref ref-type="bibr" rid="article-27852.r7">[7]</xref>&#x000a0;A small portion of this active PSA undergoes proteolysis, becoming inactive or free PSA when it enters the bloodstream and remains unbound. Active PSA that reaches the bloodstream rapidly becomes bound to circulating protease inhibitors.<xref ref-type="bibr" rid="article-27852.r8">[8]</xref>&#x000a0;The age-adjusted percent free to protein-bound PSA ratio is a useful indicator of cancer as the free PSA/total PSA ratio tends to decrease in malignancy. Please refer to "<bold>Free and Total PSA</bold>" in the <bold>Results&#x000a0;</bold>section for more information.</p>
        <p>PSA decreases seminal viscosity by chemically breaking down the proteins<bold>&#x000a0;</bold>semenogelin and fibronectin,&#x000a0;which are responsible for the initial gel-like consistency of normal semen. This reduced viscosity allows for easier sperm migration into the cervix and promotes overall fertility.<xref ref-type="bibr" rid="article-27852.r9">[9]</xref>&#x000a0;As men age, spermatozoa production is altered, with a resultant adverse effect on sperm count and quality, which impairs reproductive function.<xref ref-type="bibr" rid="article-27852.r10">[10]</xref>&#x000a0;PSA levels also increase with age, which is believed to be an evolutionary adaptation that confers genetic fitness and promotes fertility over other competing males. This adaptation may partly explain the increasing prevalence of conditions such as benign prostatic hyperplasia in the general population and the need for age-specific normal ranges for serum PSA levels. Prostate cancer cells do not produce more PSA than benign cells; in fact, they tend to manufacture less. However, malignant cells more easily allow PSA to pass through the cell wall into the surrounding extracellular fluid and eventually reach the bloodstream. This process occurs because these malignant prostate cells lack a basal layer&#x000a0;that otherwise restricts the passage of PSA outside the cell.&#x000a0;Very high Gleason score cancer cells that are highly undifferentiated may not produce PSA.</p>
      </sec>
      <sec id="article-27852.s4" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>Serum prostate-specific antigen is still a somewhat controversial screening tool for healthy, asymptomatic males&#x000a0;because elevated levels of serum PSA can be associated with various benign prostatic conditions. Infection, trauma, inflammation, and benign prostatic hyperplasia can elevate serum PSA levels, reducing the specificity of the biomarker for use in predicting prostate cancer. Studies show that up to 86% of individuals with benign prostatic hyperplasia may have elevated levels of serum PSA.<xref ref-type="bibr" rid="article-27852.r11">[11]</xref>&#x000a0;The decision to screen an asymptomatic male using serum PSA should involve shared decision-making. Such<bold>&#x000a0;</bold>discussions&#x000a0;involve&#x000a0;risks and benefits, such as a falsely elevated PSA value that may lead to an unnecessary biopsy of a benign condition or the discovery of indolent prostate cancer that can lead to the treatment of a condition that has remained totally asymptomatic and clinically inactive.</p>
        <p>The United States Preventative Task Force recommends selectively offering serum PSA screening individually according to professional judgment and patient preference in males aged 55 to 69 (grade C).<xref ref-type="bibr" rid="article-27852.r12">[12]</xref> The patient's general health is an important factor in the decision to screen, as guidelines recommend against screening individuals with a life expectancy of fewer than 10 years. Current guidelines recommend against routine prostate cancer screening with serum PSA in healthy asymptomatic individuals&#x000a0;aged 70 to 75.</p>
        <p>Many professional associations and societies have developed their guidelines. In general,&#x000a0;it is recommended that high-risk individuals begin annual PSA screenings for prostate cancer by age 45, such as those of African descent, those with a family history of prostate cancer or multiple cancers, those with Lynch syndrome, or those with known high-risk germline mutations such as <italic toggle="yes">BRCA2. </italic>For men at average risk, screenings should begin no later than 50 years, following a full discussion of the pros and cons of such testing. The testing should be continued until patients reach 70 to 75 years.&#x000a0;Due to the very high variability of PSA testing results,&#x000a0;2&#x000a0;separate specimens are recommended before conducting further investigations in patients with abnormal PSA elevations. Some clinicians prescribe a&#x000a0;2- to 6-week course of antibiotics to reduce prostatic inflammation or low-grade prostatitis, which can elevate PSA levels, before repeating the test.<xref ref-type="bibr" rid="article-27852.r13">[13]</xref><xref ref-type="bibr" rid="article-27852.r14">[14]</xref>&#x000a0;Please see StatPearls' companion reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27834">Prostate Cancer Screening</ext-link>," for more information.</p>
      </sec>
      <sec id="article-27852.s5" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Serum PSA is&#x000a0;far superior to digital rectal examination (DRE) and transrectal prostatic ultrasonography (TRUS) for detecting early prostate cancer.<xref ref-type="bibr" rid="article-27852.r15">[15]</xref>&#x000a0;When using a PSA value&#x000a0;greater than 4 ng/mL, detection rates for prostate cancer achieve a specificity of 91%. In contrast,&#x000a0;a digital rectal examination&#x000a0;is far less specific, at only 59%. Initially, the urologic and medical community heartily embraced the potential of PSA screenings to detect early prostate cancer, with the intent to avoid any disease progression and decrease mortality. However, with increased use of PSA testing, many individuals experienced adverse effects and unnecessary procedures because their PSA values were elevated secondary to benign conditions.<xref ref-type="bibr" rid="article-27852.r16">[16]</xref>&#x000a0;The risk of overdiagnosis, particularly overtreatment, can be minimized by carefully reviewing and discussing the viable options, benefits, and risks at each stage of the diagnostic process.</p>
        <p>Overall, PSA sensitivity ranges from 9% to&#x000a0;33%, depending on age and the PSA cut-off values, indicating that up to 91% of individuals with elevated serum PSA levels&#x000a0;do not have prostate cancer.<xref ref-type="bibr" rid="article-27852.r17">[17]</xref>&#x000a0;In clinical practice, the actual risk of prostate cancer in men with an elevated PSA is roughly 30%. Most malignancies found due to elevated PSA levels are low-risk prostate cancers that are often managed by monitoring with active surveillance. Only about 25% of men managed by active surveillance experience a progression of their cancer that requires definitive therapy.</p>
        <p>
<bold>Magnetic Resonance Imaging</bold>
</p>
        <p>Magnetic resonance imaging (MRI)&#x000a0;can also be used to detect prostate cancer. However, it is expensive&#x000a0;and time-consuming.&#x000a0;Other noninvasive options should be explored&#x000a0;before using MRI, as even T-1 and T-2 weighted imaging lack sufficient specificity or sensitivity to justify utilization as a screening tool. In addition, MRI can also miss about 25% of clinically significant malignancies. MRI prostate scans have been useful in identifying suspicious nodules when a decision has already been made to consider a biopsy.<xref ref-type="bibr" rid="article-27852.r17">[17]</xref></p>
        <p>
<bold>Prostate-Specific Risk Stratification Bioassays</bold>
</p>
        <p>Prostate-specific risk stratification bioassays&#x000a0;are designed to identify patients with elevated PSA levels who can safely avoid biopsies. These tests use either genomics or specific biochemical markers in the serum or urine to identify individuals with elevated PSA levels with a low likelihood of clinically significant (Gleason grade 4) cancer. All of the currently available commercial products in the United States, such as the Prostate Health Index (PHI), 4K Score, PCA3, SelectMDx, and EPI Exosome testing, have at least a 90% negative predictive value, indicating that there is less than a 10% chance of finding significant cancer if the test is negative. Between 25% and 30% of all patients having one of these prostatic bioassays ultimately test negative and can safely avoid a biopsy. MRI and bioassays prevent unnecessary, low-yield biopsies in selected, borderline, or questionable cases. Because of their cost and complexity, these tests are inappropriate for general screening.</p>
        <p>
<bold>Overdiagnosis, Overtreatment, and Unnecessary Biopsies</bold>
</p>
        <p>Overdiagnosis and overtreatment are often cited as reasons to discontinue PSA testing for prostate cancer.<xref ref-type="bibr" rid="article-27852.r18">[18]</xref></p>
        <p><bold>Overdiagnosis:&#x000a0;</bold>Overdiagnosis&#x000a0;is defined by the Institute for Quality and Efficiency in Healthcare as the diagnosis of a medical condition, disease, or disorder that has never caused the patient an earlier death or any symptoms or clinical problems. Overdiagnosis is considered harmful if it leads to unnecessary treatments or causes the patient undue psychological stress or anxiety. Overdiagnosis&#x000a0;is not a misdiagnosis or a false alarm, and it is an inevitable part of all screening tests to some degree.<xref ref-type="bibr" rid="article-27852.r18">[18]</xref><xref ref-type="bibr" rid="article-27852.r19">[19]</xref>&#x000a0;The only way to eliminate overdiagnosis is to avoid all screening tests, as it is impossible to accurately predict the course or outcome of every disease discovered through screening nor foresee all other related and unrelated medical events that might occur to the patient. The harmful effects of overdiagnosis can be minimized by carefully explaining, before PSA screening, that most men with an elevated PSA do not have cancer and that the vast majority of prostate cancers discovered by PSA testing never need treatment or cause the patient any harm. Screening tests such as PSA are never urgent;&#x000a0;therefore, patients have ample time to review the available information on screening and carefully consider their options.<xref ref-type="bibr" rid="article-27852.r18">[18]</xref><xref ref-type="bibr" rid="article-27852.r20">[20]</xref></p>
        <p>For many patients, the choice boils down to one of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Conduct regular screening tests, even if it risks possible overdiagnosis of indolent cancers,&#x000a0;which might result in procedures or treatments causing&#x000a0;psychological or physical harm.</p>
          </list-item>
          <list-item>
            <p>Avoiding screening tests eliminates overdiagnosis and potentially uncomfortable treatments. However, it also means that a potentially serious cancer is only discovered at a later stage when curative treatment is no longer effective or available.</p>
          </list-item>
        </list>
        <p><bold>Overtreatment:&#x000a0;</bold>Overtreatment of indolent prostatic cancers can cause significant physical harm, a dramatic decrease in quality of life, and may ultimately not provide any survival benefit to the patient.<xref ref-type="bibr" rid="article-27852.r18">[18]</xref>&#x000a0;The introduction of active surveillance protocols for low-risk, low-stage prostate cancer effectively eliminated overtreatment for 70% to 75% of such patients who previously received full definitive therapy. To be considered for definitive treatment, patients under active surveillance must show evidence of disease progression and meet eligibility criteria regarding life expectancy, age, and comorbidities.&#x000a0;When fully implemented, this approach can effectively eliminate most cases of prostate cancer overtreatment.<xref ref-type="bibr" rid="article-27852.r18">[18]</xref></p>
        <p><bold>Unnecessary biopsies:</bold>&#x000a0;Using pre-biopsy tools and procedures can minimize the risk of unnecessary biopsies. Prostate biopsies can be uncomfortable and lead to prolonged bleeding and infections, but they are also the only way to definitively diagnose prostate cancer, which is a potentially lethal but curable disease if caught early. Using age-adjusted PSA normal ranges and limiting PSA screenings only to those likely to benefit from treatment can help reduce unnecessary biopsies. The increasing use of&#x000a0;MRI scans and risk stratification bioassays can eliminate 25% to 30% or more of low-yield biopsies by better identifying patients unlikely to have clinically significant (Gleason grade 4) disease.</p>
        <p>Some suggest that there is no such thing as an unnecessary biopsy, as all biopsies are performed to establish a definitive diagnosis, which is what a prostate biopsy accomplishes. Labeling any biopsy as unnecessary simply because it produces a negative result is misleading; otherwise, all biopsies with negative results could also be considered unnecessary.&#x000a0;The negative effects of overdiagnosis can be substantially mitigated by carefully avoiding the treatment of indolent cancers. This mitigation can be accomplished by following the established guidelines and recommendations related to low-grade, low-stage prostate cancers, optimally using MRI scans and risk stratification bioassays, fully implementing active surveillance protocols where appropriate, and avoiding screenings in patients who do not benefit from them&#x02014;such as those who refuse biopsies and treatment, those with a life expectancy of lesser than 10 years, and asymptomatic patients older than 75.</p>
      </sec>
      <sec id="article-27852.s6" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>With the increased&#x000a0;use&#x000a0;of PSA as a screening tool for prostate cancer and its subsequent overdiagnosis and overtreatment, several national societies have revised their guidelines regarding the use of serum PSA screening. This modification has led to an effort to differentiate between clinically significant prostate cancer versus indolent disease.<xref ref-type="bibr" rid="article-27852.r21">[21]</xref>&#x000a0;Total serum PSA exists in 3 isoforms of equal concentration&#x02014;intact and free PSA, pro-PSA, and benign prostatic hyperplasia&#x02013;associated PSA. All 3 isoforms have been studied as potential biomarkers for differentiating the causes of PSA elevation.</p>
        <p>Benign prostatic hyperplasia&#x02013;associated PSA is generally found in transitional zone tissue, indicating its expression by hyperplastic prostatic tissue. A proportional increase in benign prostatic hyperplasia&#x02013;associated PSA is directly related to prostate volume and suggests benign prostatic hyperplasia.<xref ref-type="bibr" rid="article-27852.r22">[22]</xref>&#x000a0;Several studies have shown that pro-PSA, alone or preferably in combination with other markers, can serve as a valuable biomarker for more aggressive prostate cancer, as pro-PSA is associated with increasing Gleason scores.<xref ref-type="bibr" rid="article-27852.r23">[23]</xref>&#x000a0;Incorporating pro-PSA into a bioassay risk analysis profile&#x000a0;has shown promise in predicting prostate cancer in individuals with mildly elevated PSA values.<xref ref-type="bibr" rid="article-27852.r24">[24]</xref><xref ref-type="bibr" rid="article-27852.r25">[25]</xref></p>
      </sec>
      <sec id="article-27852.s7" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Screening with PSA has led to earlier detection of prostate cancer; however, morbidity increases for all patients with elevated PSA values, as a majority of the patients have a benign condition as the etiology of the elevated serum PSA. When evaluating the elevated serum values due to prostate cancer, most prostate cancers are indolent and never progress to a point in which intervention is required. As few as 2% of all elevated serum PSA values above 3 ng/mL ever require further intervention because of an aggressive form of prostate cancer.<xref ref-type="bibr" rid="article-27852.r17">[17]</xref>&#x000a0;There is no level of PSA that reliably guarantees that prostate cancer is present or absent.</p>
        <p>5-Alpha reductase inhibitors (5-ARIs) reduce PSA levels by 50%, but this effect typically takes between 6 and&#x000a0;12 months. PSA levels in men on long-term 5-ARI medications should be doubled for screening purposes. Conversely, patients should be screened for prostate cancer before starting 5-ARI medications, specifically due to the delayed effect on PSA levels and the time required for this reduction to become fully apparent. There is no significant change in prostate cancer incidence or progression in men on 5-ARI medications compared to similar male cohorts without the drugs.<xref ref-type="bibr" rid="article-27852.r26">[26]</xref>&#x000a0;</p>
        <p>Besides 5-alpha reductase inhibitors, other medications such as statins, nonsteroidal anti-inflammatory drugs, acetaminophen, and thiazide have also been shown to lower PSA levels.<xref ref-type="bibr" rid="article-27852.r27">[27]</xref><xref ref-type="bibr" rid="article-27852.r28">[28]</xref><xref ref-type="bibr" rid="article-27852.r29">[29]</xref><xref ref-type="bibr" rid="article-27852.r30">[30]</xref>&#x000a0;Obese men with high body mass index have larger intravascular volumes, so they tend to have lower PSA values solely due to this dilutional effect. Whether the normal PSA range should be adjusted for this dilution effect remains unclear.<xref ref-type="bibr" rid="article-27852.r31">[31]</xref>&#x000a0;Technical errors and inaccurate measurements of prostatic volume can lead to erroneous PSA density determinations. The use of different laboratory tests for PSA can cause some variation in the results. Prostatitis, a digital rectal examination, hard bowel movement, urologic instrumentation, and recent ejaculation can all increase PSA levels.</p>
      </sec>
      <sec id="article-27852.s8" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>There is a direct relationship between increased serum PSA levels and the likelihood of a prostate cancer diagnosis. However, determining the appropriate point for further evaluation can be unclear.<xref ref-type="bibr" rid="article-27852.r11">[11]</xref>&#x000a0;A PSA value of greater than or equal to 4.0 ng/mL is the consensus standard for further prostate cancer evaluation. This value has been shown to maximize specificity at the expense of sensitivity for prostate cancer detection. Although prostate cancer has been routinely found in individuals with PSA values above 4.0 ng/mL,&#x000a0;this value requires some individuals with prostate cancer to be missed so that fewer individuals are subjected to unnecessary biopsies.<xref ref-type="bibr" rid="article-27852.r32">[32]</xref><xref ref-type="bibr" rid="article-27852.r33">[33]</xref>&#x000a0;This situation is a trade-off&#x02014;a lower cutoff finds more cancers but requires more testing and biopsies, whereas a higher cutoff delays the detection of some potentially dangerous cancers.</p>
        <p>No PSA value can guarantee the detection of prostate cancer. Values as low as 1.1 ng/mL routinely overlook up to 17% of prostate cancers.<xref ref-type="bibr" rid="article-27852.r34">[34]</xref>&#x000a0;Using the same laboratory value (1.1 ng/mL) in Black men, 50% of cases in men aged 50 to 59, and 75% of cases in those aged 70 to 79, demonstrates laboratory values that necessitate further workup and subject untold individuals to unnecessary and uncomfortable biopsies.<xref ref-type="bibr" rid="article-27852.r35">[35]</xref>&#x000a0;By comparison, increasing the PSA cutoff value to 10 ng/mL reduces unnecessary medical evaluations for most indolent causes, but it is estimated that half of all cancers detected by PSA can no longer be organ-confined or localized, thereby negating any potential benefit of early detection.<xref ref-type="bibr" rid="article-27852.r36">[36]</xref>&#x000a0;The single general consensus standard normal upper limit for PSA is considered to be no more than 4 ng/mL (PSA is measured either in ng/mL or mcg/L. These units are equivalent, so 1 ng/mL=1 mcg/L).</p>
        <p>
<bold>Age-Adjusted Prostate-Specific Antigen </bold>
</p>
        <p>Using 4 ng/mL as the single upper normal limit for serum PSA does not adequately account for the natural increase in serum PSA expected to occur with age.&#x000a0;There is a direct correlation between age and serum PSA concentration, with an expected 3.2% increase per year demonstrated in healthy 60-year-old men.<xref ref-type="bibr" rid="article-27852.r37">[37]</xref>&#x000a0;Therefore, the age-adjusted ranges are recommended when analyzing serum PSA values.<xref ref-type="bibr" rid="article-27852.r38">[38]</xref></p>
        <p>The 95th percentile PSA value is commonly used for the age-adjusted normal reference ranges in men, which are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>40-49: &#x02264;2.5 ng/mL</p>
          </list-item>
          <list-item>
            <p>50-59: &#x02264;3.5 ng/mL</p>
          </list-item>
          <list-item>
            <p>60-69: &#x02264;4.5 ng/mL</p>
          </list-item>
          <list-item>
            <p>70-79:&#x02264;6.5 ng/mL&#x000a0;<xref ref-type="bibr" rid="article-27852.r37">[37]</xref></p>
          </list-item>
        </list>
        <p><bold>Free and Total Prostate-Specific Antigen:</bold>&#x000a0;Free PSA is a subset of intact PSA. A decrease in the ratio of this serum biomarker (free PSA/total PSA) may be used to improve the sensitivity of prostate cancer detection when initial total PSA values are between 4 and 10 ng/mL.<xref ref-type="bibr" rid="article-27852.r39">[39]</xref><xref ref-type="bibr" rid="article-27852.r40">[40]</xref>&#x000a0;Some studies have included pro-PSA in their intact PSA assay, enhancing the predictive value beyond that of intact PSA alone.<xref ref-type="bibr" rid="article-27852.r41">[41]</xref></p>
        <p>When the total PSA is between 4 and 10 ng/mL, free % PSA can be used.<xref ref-type="bibr" rid="article-27852.r37">[37]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The higher the free % PSA, the lower the risk of cancer.</p>
          </list-item>
          <list-item>
            <p>The actual cancer risk varies according to age.</p>
          </list-item>
          <list-item>
            <p>If the free % PSA is &#x0003c;10%, the cancer risk is 50%.</p>
          </list-item>
          <list-item>
            <p>If the free % PSA is &#x0003e;25%, the cancer risk is &#x0003c;10%.</p>
          </list-item>
        </list>
        <p>Please see StatPearls' companion reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27834">Prostate Cancer Screening</ext-link>," for more information.</p>
        <p><bold>Prostate-Specific Antigen Density:</bold>&#x000a0;The prostate volume in cubic centimeters can be calculated using the formula: (width cm &#x000d7; height cm &#x000d7; length cm) x 0.52. These values are measured using either an MRI or prostatic ultrasound. When the prostate volume is known, PSA density can be calculated by dividing the total PSA (ng/mL) by the prostate volume (cc). A PSA density of 0.15 or more is considered suspicious for cancer.<xref ref-type="bibr" rid="article-27852.r42">[42]</xref></p>
        <p><bold>Prostate-Specific Antigen Velocity:&#x000a0;</bold>A slow increase in PSA level is expected over time, but a more rapid rise could indicate malignancy. Generally, a yearly increase in PSA of no more than 0.75 ng/mL higher per year and no more than 25% is considered acceptable. More significant increases are considered suspicious.<xref ref-type="bibr" rid="article-27852.r43">[43]</xref>&#x000a0;Calculating the PSA velocity requires 3 separate PSA determinations over at least 18 months.</p>
        <p><bold>Prostate-Specific Antigen Doubling Time:</bold> Aggressive, rapidly growing prostate cancers are more dangerous than slow-growing malignancies, which can be estimated using the PSA doubling time in patients with known prostate cancer. A PSA doubling time of 2 years or longer is generally considered reasonably acceptable. As the PSA doubling time becomes shorter, the 5-year prostate cancer mortality rate increases. A PSA doubling time longer than 12 months is associated with a 5-year prostate cancer-specific death rate of 10% compared to those with a doubling time of 1 year or less who have a 50% mortality.<xref ref-type="bibr" rid="article-27852.r44">[44]</xref>&#x000a0;If the PSA doubling time is less than 3 months, the prostate cancer mortality rate is 20 times greater.<xref ref-type="bibr" rid="article-27852.r45">[45]</xref>&#x000a0;A higher Gleason score tends to lower the survival rate as well.</p>
        <p>
<bold>Prostate Biopsies</bold>
</p>
        <p>The decision to perform a biopsy should include at least 2 elevated PSA values and take into consideration the patient's age, comorbidities, medical history, family history, high-risk factors, physical examination, urinary symptoms, reasonable life expectancy, and personal preference after a thorough review of the risks and benefits. Results of an MRI or prostate cancer bio-assay examination, if available, should also be included. Performing a prostate biopsy can be a complicated decision. In general, biopsies should not be recommended in patients where there is an unacceptable risk, such as those who cannot safely stop anticoagulant therapy. In addition, biopsies are not appropriate for patients who do not accept treatment even if a dangerous cancer is found or for those whose life expectancy due to age or comorbidities is well below the minimum 10 years necessary to see a significant benefit from treatment. Patients should be fully informed of the risks and benefits of the biopsy and given sufficient time to decide on their choice. Please see StatPearls' companion reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27834">Prostate Cancer Screening</ext-link>," for more information.</p>
        <p>
<bold>Prostate-Specific Antigen Use in Active Surveillance of Prostate Cancer</bold>
</p>
        <p>Active surveillance for prostate cancer is based on the finding that low-grade, low-stage prostate cancer is relatively indolent, causing most patients no clinical harm. Low-risk (Gleason 3+3=6) and selected low intermediate-risk&#x000a0;(Gleason 3=4+7) patients are generally considered candidates for active surveillance. Most of these patients (about 25%) do not show any disease progression and can safely avoid the adverse effects and complications of definitive cancer therapy.</p>
        <p>A repeat biopsy 6 to 18 months after the initial diagnosis is the standard of care for patients on active surveillance, given the high reported rate of pathological reclassification of up to 35% after the second confirmatory biopsy.<xref ref-type="bibr" rid="article-27852.r46">[46]</xref><xref ref-type="bibr" rid="article-27852.r47">[47]</xref><xref ref-type="bibr" rid="article-27852.r48">[48]</xref>&#x000a0;</p>
        <p>Prostate MRIs are recommended before the rebiopsy to optimize results and monitor the progress of any identifiable lesions.<xref ref-type="bibr" rid="article-27852.r49">[49]</xref><xref ref-type="bibr" rid="article-27852.r50">[50]</xref><xref ref-type="bibr" rid="article-27852.r51">[51]</xref><xref ref-type="bibr" rid="article-27852.r52">[52]</xref>&#x000a0;For higher-risk patients on active surveillance&#x02014;such as those with African ancestry, high PSA density (0.15 or more), a family history of prostate cancer, or positive for high-risk genomic biomarkers&#x02014;both an MRI and a repeat biopsy are suggested. PSA monitoring for patients on active surveillance is generally performed every 6 months. A significant change is generally considered a PSA level greater than 0.75 ng/mL or more than 25% a year, a PSA doubling time of less than 3 years, or a total PSA greater than 10 ng/mL. A notable change in the MRI Prostate Imaging Reporting and Data System (PI-RADS) score (from PI-RADS 3 to PI-RADS 4 or 5) or marked enlargement of a known cancer nodule&#x000a0;is also considered significant and prompts a rebiopsy.</p>
        <p>For men with stable PSA levels and digital rectal examinations, follow-up prostate biopsies after the initial confirmatory rebiopsy should generally be considered every 2 to 4 years, and&#x000a0;MRI scans should be repeated every 1&#x000a0;to 2 years, depending on risk factors and comorbidities. MRI alone is not reliable enough to completely supplant prostate biopsies.<xref ref-type="bibr" rid="article-27852.r53">[53]</xref><xref ref-type="bibr" rid="article-27852.r54">[54]</xref><xref ref-type="bibr" rid="article-27852.r55">[55]</xref><xref ref-type="bibr" rid="article-27852.r56">[56]</xref>&#x000a0;The suggested protocol was compared to an alternate regimen where repeat biopsies were performed after the initial confirmatory biopsy only when significant changes in the MRI scan or PSA level were detected. This regimen eliminated many prostate biopsies compared to a scheduled protocol but missed too many clinically significant cancers.<xref ref-type="bibr" rid="article-27852.r57">[57]</xref>&#x000a0;The use of finasteride or dutasteride, 5-alpha-reductase inhibitors, and enzalutamide, an androgen receptor inhibitor, has not been shown to significantly affect slowing PSA level increases or cancer progression in patients on active surveillance.<xref ref-type="bibr" rid="article-27852.r58">[58]</xref><xref ref-type="bibr" rid="article-27852.r59">[59]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Prostate-Specific Antigen After Definitive Prostate Cancer Therapy</bold>
</p>
        <p>Overall, a recurrence rate after definitive therapy, either radical surgery or radiation, is expected in 25% to 40% of patients who undergo definitive curative treatment.<xref ref-type="bibr" rid="article-27852.r60">[60]</xref><xref ref-type="bibr" rid="article-27852.r61">[61]</xref></p>
        <p><bold>Radical prostatectomy:</bold> Following a radical prostatectomy, all prostatic tissue should&#x000a0;be removed. Therefore, any detectable PSA following the surgery indicates some remaining prostatic tissue, which is typically presumed to be cancerous.<xref ref-type="bibr" rid="article-27852.r62">[62]</xref> This prostatic tissue could be either localized or metastatic disease. Generally, if the PSA is undetectable for 2 years or longer and then gradually begins to rise, a locally recurrent cancer in the prostatic bed is likely.<xref ref-type="bibr" rid="article-27852.r63">[63]</xref><xref ref-type="bibr" rid="article-27852.r64">[64]</xref>&#x000a0;Conversely, if the PSA rises quickly and never becomes undetectable after surgery, metastatic disease is more likely.<xref ref-type="bibr" rid="article-27852.r63">[63]</xref><xref ref-type="bibr" rid="article-27852.r65">[65]</xref>&#x000a0;Slowly rising PSA levels are sometimes caused by a small amount of residual prostate tissue left behind after surgery, which occurs in 5% to 15% of all radical prostatectomy patients and does not necessarily indicate residual cancer. Adjunctive therapy should be considered if the PSA level reaches 0.4 ng/mL or more. The American Urological Association (AUA) guidelines on localized prostate cancer define a post-radical prostatectomy biochemical recurrence as 2 consecutive serum PSA levels greater than 0.2 ng/mL.<xref ref-type="bibr" rid="article-27852.r66">[66]</xref></p>
        <p><bold>Radiation therapy: </bold>After definitive radiation therapy, PSA levels typically decrease gradually, often taking up to 18 months to reach their lowest point (nadir).<xref ref-type="bibr" rid="article-27852.r67">[67]</xref>&#x000a0;The lower the final nadir achieved, the better the cancer-specific prognosis.<xref ref-type="bibr" rid="article-27852.r60">[60]</xref><xref ref-type="bibr" rid="article-27852.r68">[68]</xref>&#x000a0;A biochemical recurrence after definitive radiation therapy is defined as 2 PSA levels &#x0003e;2 ng/mL above the nadir level.<xref ref-type="bibr" rid="article-27852.r69">[69]</xref>&#x000a0;The need for 2 levels is due to the phenomenon known as the PSA bounce, which typically occurs 12 to 18 months after initial radiation therapy.<xref ref-type="bibr" rid="article-27852.r70">[70]</xref> There is no way to determine&#x000a0;whether this represents a true recurrence except by following the PSA levels and finding the PSA increase to be only transient. The clinical significance of the PSA bounce remains unclear.<xref ref-type="bibr" rid="article-27852.r70">[70]</xref>&#x000a0;In a large retrospective study involving 2694 men, all treated with external beam radiation therapy for localized prostate cancer, those who demonstrated a biochemical recurrence developed metastases at a median of 5.4 years.<xref ref-type="bibr" rid="article-27852.r71">[71]</xref> Prostate cancer-specific mortality was at 10.5 years. Negative prognostic factors included a higher initial Gleason score, a more advanced initial cancer staging, a shorter time interval from initial treatment to biochemical failure, and a faster PSA doubling time.<xref ref-type="bibr" rid="article-27852.r71">[71]</xref></p>
        <p>
<bold>European Urological Association Risk Stratification for Progression After Biochemical Prostate-Specific Antigen Recurrence</bold>
</p>
        <p>Biochemical recurrence after definitive therapy for localized prostate cancer is a significant, independent risk factor for metastatic disease, cancer-specific mortality, and overall mortality. The European Urological Association has suggested the following high- and low-risk stratification categories for both post-radical prostatectomy surgery and radiation therapy patients.<xref ref-type="bibr" rid="article-27852.r72">[72]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Low-risk
<list list-type="bullet"><list-item><p>After radical prostatectomy: PSA doubling time &#x0003e;12 months and Gleason score &#x0003c;8</p></list-item><list-item><p>After radiation therapy: Interval to biochemical failure &#x0003e;18 months and Gleason score &#x0003c;8</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>High-risk
<list list-type="bullet"><list-item><p>After radical prostatectomy: PSA doubling time &#x0003c;12 months and Gleason score &#x0003e;7</p></list-item><list-item><p>After radiation therapy: Interval to biochemical failure and Gleason score&#x000a0;&#x0003e;7</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Positron Emission Tomography Scans for Post-Prostatectomy Biochemical Prostate-Specific Antigen Recurrence&#x000a0;</bold>
</p>
        <p>When the PSA level is greater than 0.2 ng/mL, prostatic positron emission tomography (PET) scanning can be performed&#x000a0;to differentiate localized recurrences in the prostatic bed after radical prostatectomies that might benefit from pelvic irradiation from those with disseminated disease where systemic treatment is preferred. Some experts recommend PET scans for all post-radical prostatectomy patients with a biochemical recurrence and suitable PSA levels. In contrast, others suggest a more selective approach using a risk stratification model.</p>
      </sec>
      <sec id="article-27852.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Early prostate cancer is generally asymptomatic, and an elevated serum PSA level is often the first indication of malignancy. Anemia and elevated alkaline phosphatase levels are additional laboratory values that may suggest prostate cancer but are very nonspecific and typically indicate advanced disease, making them useless for screening or early detection. A digital rectal examination (DRE) should be performed on all individuals with abnormal PSA levels even though no specific finding reliably confirms either the presence or absence of prostate cancer. DRE is used to improve the overall sensitivity of the screening and could be an important factor in determining management if cancer is detected.</p>
        <p>Overall, up to 14% of patients with prostate cancer&#x000a0;have metastatic disease at the time of diagnosis. The finding of metastatic prostate cancer can be correlated with elevated PSA values.&#x000a0;Serum PSA values greater than 20 ng/mL have a positive predictive value of 65% for metastatic disease and skeletal involvement. This number increases linearly with a positive predictive value for metastatic disease of 86% for PSA levels greater than 100 ng/mL.<xref ref-type="bibr" rid="article-27852.r73">[73]</xref>&#x000a0;However, it should not be assumed that an individual with serum PSA values&#x000a0;&#x0003e;100 ng/mL&#x000a0;at the time of diagnosis has metastatic disease. By comparison, serum PSA values less than 10 ng/mL rarely demonstrate metastatic disease or skeletal spread. For this reason, bone scans in prostate cancer are not generally recommended unless the PSA levels are greater than 20 ng/mL.<xref ref-type="bibr" rid="article-27852.r74">[74]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27852.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>No PSA value guarantees the presence or absence of prostate cancer. Despite being controversial, nonspecific, and imperfect, PSA testing is currently still the best and most sensitive early indicator of an asymptomatic prostatic malignancy. The decision to screen healthy individuals using the test likely continues to be controversial. Individuals aged 45 to 75 should be given the option for screening after discussing the risks and benefits, with particular consideration given to patient preference, age, comorbidities, and family history. Following the decision to screen, PSA values&#x000a0;are instrumental in determining the next steps in treatment. Generally, low PSA values in asymptomatic individuals are reassuring, and significantly elevated PSA values are concerning for prostate cancer.</p>
        <p>Some of the drawbacks of screening can be minimized through risk stratification strategies and&#x000a0;recognizing the potential for overtreatment in low-risk diseases. All healthcare team members should be aware of the controversies involved and be prepared to assist the patient in decision-making. There is no controversy regarding the use of PSA testing in patients with known malignant diseases. In these cases, the team should encourage patients to be involved in their healthcare decisions, adhere to follow-up PSA tests according to clinician recommendations, and follow published guidelines&#x000a0;to achieve optimal outcomes.</p>
      </sec>
      <sec id="article-27852.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27852&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27852">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27852/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27852">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27852.s12">
        <title>References</title>
        <ref id="article-27852.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dvor&#x000e1;cek</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Adenocarcinoma of the prostate].</article-title>
            <source>Cas Lek Cesk</source>
            <year>1998</year>
            <month>Aug</month>
            <day>31</day>
            <volume>137</volume>
            <issue>17</issue>
            <fpage>515</fpage>
            <page-range>515-21</page-range>
            <pub-id pub-id-type="pmid">9787503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2020.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-30</page-range>
            <pub-id pub-id-type="pmid">31912902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>The economic burden of prostate cancer.</article-title>
            <source>BJU Int</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-13</page-range>
            <pub-id pub-id-type="pmid">21884356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plata Bello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Concepcion Masip</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer epidemiology.</article-title>
            <source>Arch Esp Urol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-82</page-range>
            <pub-id pub-id-type="pmid">24914835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etzioni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsodikov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mariotto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szabo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falcon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wegelin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DiTommaso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karnofski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Penson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Quantifying the role of PSA screening in the US prostate cancer mortality decline.</article-title>
            <source>Cancer Causes Control</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-81</page-range>
            <pub-id pub-id-type="pmid">18027095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpert</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients.</article-title>
            <source>Urology</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>118</volume>
            <fpage>119</fpage>
            <page-range>119-126</page-range>
            <pub-id pub-id-type="pmid">29772218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schedlich</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bennetts</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Primary structure of a human glandular kallikrein gene.</article-title>
            <source>DNA</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>429</fpage>
            <page-range>429-37</page-range>
            <pub-id pub-id-type="pmid">2824146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikolajczyk</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Free prostate-specific antigen in serum is becoming more complex.</article-title>
            <source>Urology</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>797</fpage>
            <page-range>797-802</page-range>
            <pub-id pub-id-type="pmid">12031356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Three predominant proteins secreted by the human prostate gland.</article-title>
            <source>Prostate</source>
            <year>1988</year>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-38</page-range>
            <pub-id pub-id-type="pmid">3347596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hekim</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Arslan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Asci</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of aging on the male reproductive system.</article-title>
            <source>J Assist Reprod Genet</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>441</fpage>
            <page-range>441-54</page-range>
            <pub-id pub-id-type="pmid">26867640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamey</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>McNeal</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Freiha</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Redwine</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.</article-title>
            <source>N Engl J Med</source>
            <year>1987</year>
            <month>Oct</month>
            <day>08</day>
            <volume>317</volume>
            <issue>15</issue>
            <fpage>909</fpage>
            <page-range>909-16</page-range>
            <pub-id pub-id-type="pmid">2442609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>US Preventive Services Task Force</collab>
              <name>
                <surname>Grossman</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Bibbins-Domingo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caughey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Doubeni</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ebell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epling</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Krist</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kubik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landefeld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>May</month>
            <day>08</day>
            <volume>319</volume>
            <issue>18</issue>
            <fpage>1901</fpage>
            <page-range>1901-1913</page-range>
            <pub-id pub-id-type="pmid">29801017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toktas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Demiray</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erkan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kocaaslan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yucetas</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Unluer</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The effect of antibiotherapy on prostate-specific antigen levels and prostate biopsy results in patients with levels 2.5 to 10&#x02009;ng/mL.</article-title>
            <source>J Endourol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>1061</fpage>
            <page-range>1061-7</page-range>
            <pub-id pub-id-type="pmid">23641793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taha</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Aboumarzouk</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Koraiem</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Shokeir</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review.</article-title>
            <source>Arab J Urol</source>
            <year>2020</year>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">32082627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ratliff</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Dodds</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Coplen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Petros</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>Apr</month>
            <day>25</day>
            <volume>324</volume>
            <issue>17</issue>
            <fpage>1156</fpage>
            <page-range>1156-61</page-range>
            <pub-id pub-id-type="pmid">1707140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albertsen</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer screening with prostate-specific antigen: Where are we going?</article-title>
            <source>Cancer</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-455</page-range>
            <pub-id pub-id-type="pmid">29231972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Welton</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolstenholme</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.</article-title>
            <source>Cancer Epidemiol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>52</volume>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">29278842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klotz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer overdiagnosis and overtreatment.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>204</fpage>
            <page-range>204-9</page-range>
            <pub-id pub-id-type="pmid">23609043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bulliard</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chiolero</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Screening and overdiagnosis: public health implications.</article-title>
            <source>Public Health Rev</source>
            <year>2015</year>
            <volume>36</volume>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">29450036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moynihan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Doust</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Preventing overdiagnosis: how to stop harming the healthy.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>May</month>
            <day>28</day>
            <volume>344</volume>
            <fpage>e3502</fpage>
            <pub-id pub-id-type="pmid">22645185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palapattu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.</article-title>
            <source>Curr Urol Rep</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>63</fpage>
            <pub-id pub-id-type="pmid">26169584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okihara</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Role of complexed PSA in the early detection of prostate cancer.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2004</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-12</page-range>
            <pub-id pub-id-type="pmid">19795605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kagan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mizrahi</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Broyles</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2010</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>1193</fpage>
            <page-range>1193-200</page-range>
            <pub-id pub-id-type="pmid">20447916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazzeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de la Taille</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palou Redorta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McNicholas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lughezzani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scattoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Freschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghaleh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Le Corvoisier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alberola Bou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Esquena Fern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Graefen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guazzoni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.</article-title>
            <source>Eur Urol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>986</fpage>
            <page-range>986-94</page-range>
            <pub-id pub-id-type="pmid">23375961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Klee</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Slawin</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Broyles</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>van Schaik</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Mizrahi</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.</article-title>
            <source>J Urol</source>
            <year>2011</year>
            <month>May</month>
            <volume>185</volume>
            <issue>5</issue>
            <fpage>1650</fpage>
            <page-range>1650-5</page-range>
            <pub-id pub-id-type="pmid">21419439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zkan</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Cebeci</surname>
                <given-names>O&#x000d6;</given-names>
              </name>
              <name>
                <surname>&#x000c7;evik</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>Dillio&#x0011f;lugil</surname>
                <given-names>&#x000d6;</given-names>
              </name>
            </person-group>
            <article-title>Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance.</article-title>
            <source>Turk J Urol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-137</page-range>
            <pub-id pub-id-type="pmid">29511582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Palapattu</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>van Wijngaarden</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Oct</month>
            <day>15</day>
            <volume>113</volume>
            <issue>8</issue>
            <fpage>2053</fpage>
            <page-range>2053-7</page-range>
            <pub-id pub-id-type="pmid">18780337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Harshman</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Presti</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>01</day>
            <volume>28</volume>
            <issue>25</issue>
            <fpage>3951</fpage>
            <page-range>3951-7</page-range>
            <pub-id pub-id-type="pmid">20679596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Platz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>The influence of statin medications on prostate-specific antigen levels.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2008</year>
            <month>Nov</month>
            <day>05</day>
            <volume>100</volume>
            <issue>21</issue>
            <fpage>1511</fpage>
            <page-range>1511-8</page-range>
            <pub-id pub-id-type="pmid">18957682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mondul</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Selvin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Marzo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Platz</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004.</article-title>
            <source>Cancer Causes Control</source>
            <year>2010</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>671</fpage>
            <page-range>671-8</page-range>
            <pub-id pub-id-type="pmid">20072809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ba&#x000f1;ez</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Vollmer</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Terris</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Presti</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Amling</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Moul</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>Nov</month>
            <day>21</day>
            <volume>298</volume>
            <issue>19</issue>
            <fpage>2275</fpage>
            <page-range>2275-80</page-range>
            <pub-id pub-id-type="pmid">18029831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.</article-title>
            <source>Cancer</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>894</fpage>
            <page-range>894-904</page-range>
            <pub-id pub-id-type="pmid">15329895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.</article-title>
            <source>Prostate</source>
            <year>2006</year>
            <month>Jul</month>
            <day>01</day>
            <volume>66</volume>
            <issue>10</issue>
            <fpage>1044</fpage>
            <page-range>1044-51</page-range>
            <pub-id pub-id-type="pmid">16598738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Ankerst</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lucia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Parnes</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Coltman</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.</article-title>
            <source>JAMA</source>
            <year>2005</year>
            <month>Jul</month>
            <day>06</day>
            <volume>294</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-70</page-range>
            <pub-id pub-id-type="pmid">15998892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Moul</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Age-specific reference ranges for serum prostate-specific antigen in black men.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Aug</month>
            <day>01</day>
            <volume>335</volume>
            <issue>5</issue>
            <fpage>304</fpage>
            <page-range>304-10</page-range>
            <pub-id pub-id-type="pmid">8663870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Herschman</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Longitudinal screening for prostate cancer with prostate-specific antigen.</article-title>
            <source>JAMA</source>
            <year>1996</year>
            <month>Oct</month>
            <day>23-30</day>
            <volume>276</volume>
            <issue>16</issue>
            <fpage>1309</fpage>
            <page-range>1309-15</page-range>
            <pub-id pub-id-type="pmid">8861989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oesterling</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chute</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Guess</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Girman</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Panser</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lieber</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.</article-title>
            <source>JAMA</source>
            <year>1993</year>
            <month>Aug</month>
            <day>18</day>
            <volume>270</volume>
            <issue>7</issue>
            <fpage>860</fpage>
            <page-range>860-4</page-range>
            <pub-id pub-id-type="pmid">7688054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Criley</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Subong</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Zincke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Oesterling</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.</article-title>
            <source>J Urol</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>155</volume>
            <issue>4</issue>
            <fpage>1336</fpage>
            <page-range>1336-9</page-range>
            <pub-id pub-id-type="pmid">8632568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vickers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bjartell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manjer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ulmert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-61</page-range>
            <pub-id pub-id-type="pmid">21148123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vickers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Peltola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.</article-title>
            <source>Clin Cancer Res</source>
            <year>2010</year>
            <month>Jun</month>
            <day>15</day>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>3232</fpage>
            <page-range>3232-9</page-range>
            <pub-id pub-id-type="pmid">20400522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peltola</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Niemel&#x000e4;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>V&#x000e4;is&#x000e4;nen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Viitanen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alanen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nurmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades.</article-title>
            <source>Urology</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>1009.e1</fpage>
            <page-range>1009.e1-8</page-range>
            <pub-id pub-id-type="pmid">21296394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kosaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hongo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shinojima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miyajima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jinzaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oya</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>656</fpage>
            <page-range>656-660</page-range>
            <pub-id pub-id-type="pmid">30546897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vickers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Brewster</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.</article-title>
            <source>Br J Med Surg Urol</source>
            <year>2012</year>
            <month>Jul</month>
            <day>01</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>162</fpage>
            <page-range>162-168</page-range>
            <pub-id pub-id-type="pmid">22712027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coley</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mulley</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians.</article-title>
            <source>Ann Intern Med</source>
            <year>1997</year>
            <month>Mar</month>
            <day>01</day>
            <volume>126</volume>
            <issue>5</issue>
            <fpage>394</fpage>
            <page-range>394-406</page-range>
            <pub-id pub-id-type="pmid">9054286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amico</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Moul</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lubeck</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2003</year>
            <month>Sep</month>
            <day>17</day>
            <volume>95</volume>
            <issue>18</issue>
            <fpage>1376</fpage>
            <page-range>1376-83</page-range>
            <pub-id pub-id-type="pmid">13130113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffield</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.</article-title>
            <source>J Urol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>182</volume>
            <issue>5</issue>
            <fpage>2274</fpage>
            <page-range>2274-8</page-range>
            <pub-id pub-id-type="pmid">19758635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ploussard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xylinas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allory</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vordos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoznek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abbou</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>de la Taille</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?</article-title>
            <source>J Urol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>183</volume>
            <issue>2</issue>
            <fpage>539</fpage>
            <page-range>539-44</page-range>
            <pub-id pub-id-type="pmid">20006888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kearns</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Faino</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Fabrizio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gleave</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.</article-title>
            <source>Eur Urol</source>
            <year>2018</year>
            <month>May</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>706</fpage>
            <page-range>706-712</page-range>
            <pub-id pub-id-type="pmid">29433973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nordstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>J&#x000e4;derling</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Egevad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vigneswaran</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Annerstedt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;nberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lantz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2021</year>
            <month>May</month>
            <day>04</day>
            <volume>113</volume>
            <issue>5</issue>
            <fpage>632</fpage>
            <page-range>632-640</page-range>
            <pub-id pub-id-type="pmid">32866231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scheltema</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shnier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blazevski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cusick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Siriwardena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delprado</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>May</month>
            <volume>203</volume>
            <issue>5</issue>
            <fpage>910</fpage>
            <page-range>910-917</page-range>
            <pub-id pub-id-type="pmid">31825297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamoen</surname>
                <given-names>EHJ</given-names>
              </name>
              <name>
                <surname>Hoeks</surname>
                <given-names>CMA</given-names>
              </name>
              <name>
                <surname>Somford</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>van Oort</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Vergunst</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oddens</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Smits</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Bokhorst</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rovers</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hulsbergen-van de Kaa</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Barentsz</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.</article-title>
            <source>Eur Urol Focus</source>
            <year>2019</year>
            <month>May</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>407</fpage>
            <page-range>407-415</page-range>
            <pub-id pub-id-type="pmid">29331622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stavrinides</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giganti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trock</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Punwani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kirkham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCartan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Orczyk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Emberton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.</article-title>
            <source>Eur Urol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>443</fpage>
            <page-range>443-451</page-range>
            <pub-id pub-id-type="pmid">32360049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luckenbaugh</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Auffenberg</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Hawken</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Dhir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Linsell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DC</given-names>
              </name>
              <collab>Michigan Urological Surgery Improvement Collaborative</collab>
            </person-group>
            <article-title>Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.</article-title>
            <source>J Urol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>197</volume>
            <issue>3 Pt 1</issue>
            <fpage>621</fpage>
            <page-range>621-626</page-range>
            <pub-id pub-id-type="pmid">27663459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajwa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Quhal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Laukhtina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huebner</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krzywon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Baltzer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Renard-Penna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leapman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Ploussard</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>549</fpage>
            <page-range>549-563</page-range>
            <pub-id pub-id-type="pmid">34020828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bekelman</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rumble</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Pisansky</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feifer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Loblaw</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Tagawa</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Gillessen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vapiwala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haluschak</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Touijer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kungel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>10</day>
            <volume>36</volume>
            <issue>32</issue>
            <fpage>3251</fpage>
            <page-range>3251-3258</page-range>
            <pub-id pub-id-type="pmid">30183466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eastham</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Auffenberg</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Crispino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Eggener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kirkby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Morgans</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pierorazio</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>208</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-25</page-range>
            <pub-id pub-id-type="pmid">35536148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chesnut</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Vertosick</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Benfante</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sjoberg</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Fainberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eastham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laudone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Touijer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ehdaie</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.</article-title>
            <source>Eur Urol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>501</fpage>
            <page-range>501-507</page-range>
            <pub-id pub-id-type="pmid">31874726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashrafi</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marien</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shoji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ukimura</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bahn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Abreu</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Five-alpha reductase inhibitors in men undergoing active surveillance for prostate cancer: impact on treatment and reclassification after 6&#x000a0;years follow-up.</article-title>
            <source>World J Urol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>3295</fpage>
            <page-range>3295-3307</page-range>
            <pub-id pub-id-type="pmid">33683411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shore</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Renzulli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fleshner</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Hollowell</surname>
                <given-names>CMP</given-names>
              </name>
              <name>
                <surname>Vourganti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hairston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elsouda</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cooperberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tomlins</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.</article-title>
            <source>JAMA Oncol</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>1128</fpage>
            <page-range>1128-1136</page-range>
            <pub-id pub-id-type="pmid">35708696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <article-title>Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1997</year>
            <month>Mar</month>
            <day>15</day>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>1035</fpage>
            <page-range>1035-41</page-range>
            <pub-id pub-id-type="pmid">9169810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Zahurak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piantadosi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>169</volume>
            <issue>2</issue>
            <fpage>517</fpage>
            <page-range>517-23</page-range>
            <pub-id pub-id-type="pmid">12544300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravery</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources.</article-title>
            <source>Semin Urol Oncol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>127</fpage>
            <page-range>127-9</page-range>
            <pub-id pub-id-type="pmid">10462314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Pound</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.</article-title>
            <source>Urology</source>
            <year>1994</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>649</fpage>
            <page-range>649-59</page-range>
            <pub-id pub-id-type="pmid">7513108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pound</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Eisenberger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Natural history of progression after PSA elevation following radical prostatectomy.</article-title>
            <source>JAMA</source>
            <year>1999</year>
            <month>May</month>
            <day>05</day>
            <volume>281</volume>
            <issue>17</issue>
            <fpage>1591</fpage>
            <page-range>1591-7</page-range>
            <pub-id pub-id-type="pmid">10235151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pound</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.</article-title>
            <source>Urol Clin North Am</source>
            <year>1997</year>
            <month>May</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>395</fpage>
            <page-range>395-406</page-range>
            <pub-id pub-id-type="pmid">9126237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Aus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Canby-Hagino</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Eton</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Higano</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Moul</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Tangen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thrasher</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>177</volume>
            <issue>2</issue>
            <fpage>540</fpage>
            <page-range>540-5</page-range>
            <pub-id pub-id-type="pmid">17222629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crook</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Choan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Esche</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure.</article-title>
            <source>Urology</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>566</fpage>
            <page-range>566-72</page-range>
            <pub-id pub-id-type="pmid">9586608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Thames</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kupelian</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pisansky</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>WU</given-names>
              </name>
              <name>
                <surname>Zelefsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kuban</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2006</year>
            <month>Mar</month>
            <day>15</day>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>1140</fpage>
            <page-range>1140-50</page-range>
            <pub-id pub-id-type="pmid">16198506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hanks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thames</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schellhammer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>WU</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2006</year>
            <month>Jul</month>
            <day>15</day>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>965</fpage>
            <page-range>965-74</page-range>
            <pub-id pub-id-type="pmid">16798415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishiyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsumura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayakawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ebara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kumon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kanazawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Egawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yorozu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.</article-title>
            <source>BJU Int</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>103</volume>
            <issue>8</issue>
            <fpage>1064</fpage>
            <page-range>1064-8</page-range>
            <pub-id pub-id-type="pmid">19040526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zumsteg</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Spratt</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Romesser</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Polkinghorn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kollmeier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zelefsky</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1009</fpage>
            <page-range>1009-1016</page-range>
            <pub-id pub-id-type="pmid">25308970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van den Broeck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van den Bergh</surname>
                <given-names>RCN</given-names>
              </name>
              <name>
                <surname>Briers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cornford</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cumberbatch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tilki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Santis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fossati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gillessen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grummet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lardas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moris</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schoots</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van der Poel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wiegel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Willemse</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rouvi&#x000e8;re</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Mottet</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.</article-title>
            <source>Eur Urol Focus</source>
            <year>2020</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-234</page-range>
            <pub-id pub-id-type="pmid">31248850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lojanapiwat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Anutrakulchai</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chongruksut</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Udomphot</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.</article-title>
            <source>Prostate Int</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-9</page-range>
            <pub-id pub-id-type="pmid">25325025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27852.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rhoden</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>GZ</given-names>
              </name>
              <name>
                <surname>Lemos</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Souto</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy.</article-title>
            <source>Int Braz J Urol</source>
            <year>2003</year>
            <season>Mar-Apr</season>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-5; discussion 126</page-range>
            <pub-id pub-id-type="pmid">15745494</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
